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stimulate further studies to establish a prediction tool for progression
of coronary heart disease.
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Association of serum sSema4D level with coronary atherosclerotic disease
Long Kuang, Liangping Zhao, Jianchang Chen, Weiting Xu
Department of Cardiology, Second Afﬁliated Hospital, Soochow
University
OBJECTIVES Recent studies showed that sema4D has signiﬁcant role
in atherosclerosis and thrombosis. Elevation in Sema4D level is
considered to be a novel risk factor for thrombotic disease. Being a
research highlight these years, there has been little real-world clinical
studies on Sema4D so far.
METHODS 1. 158 consecutive inpatients from the department of car-
diology in the 2nd afﬁliated hospital of Soochow University was
included in this study. The sum consist of stable 53 cases with angina
pectoris, 105 with Acute Coronary Syndrome. There were 59 subjects
in the healthy control group.
2. Enzyme-linked immunosorbent assay was utilized to test the
serum level of Sema4D.
3. All subjects underwent coronary angiography after admission,
diameter method was used to quantify the extent of coronary arterial
stenosis, which was then put into calculation with Gensini Score.
4. According to cutoff of sSema4D derived from receiver operator
curve, patients were divided into high sSema4D group (n¼95) and low
sSema4D group (n¼63). Follow-up of major adverse cardiovascular
events each 3 months was carried out within one year after discharge.
Survival analysis between both groups was performed using Kaplan-
Meier Method.
RESULTS 1. Coronary atherosclerotic disease group had signiﬁcantly
higher level of serum sSema4D compared with control (9.232.64 vs
3.931.39ng/mL, P<0.001). Moreover, patients with acute coronary
syndrome had elevated serum sSema4D level compared with those
with stable coronary atherosclerotic disease(10.132.54 vs
7.461.80ng/mL, P<0.001).
2. Patients with Gensini score over 40(11.492.73ng/mL) showed
signiﬁcantly increased serum sSema4D level compare with those
with Gensini score under 20(7.632.16ng/mL) or 20 through
40(9.531.97ng/mL).(P<0.05)
3. Serum sSema4D was positively correlated with Gensini Score
(r¼0.662, P<0.001) according to linear correlation analysis
4. Multivariate logistic regression analysis revealed that serum
sSema4D was an independent risk factor for coronary atherosclerotic
disease(OR¼7.18, 95% CI: 3.38w15.23, P<0.001) as well as for major
adverse cardiovascular events(OR¼3.178, 95% CI: 1.025w9.849,
P<0.05).
5. In patients from coronary atherosclerotic disease group, subjects
with increased level of sSema4D showed decreased major adverse
cardiovascular events-free survival rate compared with those with
relatively lower level of sSema4D(log-rank test c2¼15.149, P<0.01).
CONCLUSIONS 1. Serum sSema4D was increased in coronary athero-
sclerotic disease and even more elevated in acute coronary syndrome.
2. The positive correlation between sSema4D and Gensini score in-
dicates that sSema4D level can reﬂect the severity of coronary arterial
lesion.
3. sSema4D can be used to predict the prognosis of coronary
atherosclerotic diseases it was found to be an independent risk factor
for major adverse cardiovascular events.
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OBJECTIVES Ticagrelor provides more potent platelet inhibition than
clopidogrel, however, enhanced efﬁcacy of ticagrelor increases the
risk of bleeding and dyspnea side effects. This study sought to display
the role of ADP-induced platelet-ﬁbrin clot strength for the prediction
of bleeding and dyspnea side effect in ticagrelor treated Chinese acute
coronary syndrome (ACS) patients.
METHODS Consecutive Chinese-Han patients with ACS who received
maintenance dose of ticagrelor (90 mg, bid) and aspirin (100mg, qd)
were recruited from General Hospital of Chinese People’s LiberationArmy. After 5 days ticagrelor maintenance treatment, ADP-induced
platelet-ﬁbrin clot strength (MAADP) measured by thrombelastography
(TEG) were recorded. Pre-speciﬁed cutoffs of MAADP with consensus
for high on-treatment platelet reactivity (HTPR) and low on-treatment
platelet reactivity (LTPR) to ADP associated with ischemia and
bleeding events were applied for evaluation. Bleeding events ac-
cording to TIMI criteria and ticagrelor related dyspnea side effect were
recorded after a follow-up of 3 months.
RESULTS Overall, 532 ACS patients (Male: 72.56%, Age:6011 years)
under ticagrelor maintenance treatment were recruited. Antiplatelet
responsiveness measured by TEG was available in 176 patients. After 5
days’ ticagrelor maintenance treatment, the value of MAADP was
(21.2712.07)% on average (ranged from 4.8% to 72.9%). With the pre-
speciﬁc cutoffs for HTPR (TEG-MAADP>47mm) and LTPR (TEG-
MAADP<31mm), 7 patients (3.98%) were identiﬁed as HTPR and143
patients (81.25%) as LTPR. Among 89 patients who were followed up
for 3 months, bleeding events occurred in 43 patients (48.31%), with
major bleeding in 3 patients (3.37%), and minor bleeding in 40 pa-
tients (44.94%). All patients with major bleeding events were classi-
ﬁed as LTPR. The distribution of patients with minor bleeding events
was 3 (42.86%) in HTPR and 27 (18.88%) in LTPR, respectively. Tica-
grelor related dyspnea side effect occurred in 22 patients (24.71%),
and all of them were classiﬁed as LTPR.
CONCLUSIONS ADP-induced platelet-ﬁbrin clot strength (MAADP) as
measured by TEG could predict major bleeding and dyspnea side ef-
fects in ticagrelor treated ACS patients.
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vascular index in old patients with atherosclerotic cardiovascular diseases
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P.R. China
OBJECTIVES Enhanced external counterpulsation (EECP) therapy
enhances coronary perfusion, lowers symptom episodes and improves
quality of life in patients with atherosclerotic cardiovascular diseases
(ASCVD). However, there is little understanding about the impact of
EECP therapy on arteriosclerosis in this population. Our aim was to
investigate the effects of EECP on arterial stiffness which was iden-
tiﬁed by a novel markerdcardioankle vascular index(CAVI), and
evaluate what factors were cruel to inﬂuence the improvement of
CAVI following EECP treatment in old patients with ASCVD.
METHODS One hundred and three old individuals(mean age:70.3 9.7
years) who were diagnosed with ASCVD enrolled consecutively in the
study from Mar. 2014 to Oct. 2014. A prospective observational lon-
gitudinal study was conducted to investigate the changes of arterial
wall stiffness assessed using CAVI after 35 sessions of 1-hr daily EECP
treatment in these patients.
RESULTS Compared with baseline values, LVEF value increased and
plasma concentrations of NT-proBNP, hs-CRP, and homocysteine
signiﬁcantly decreased at the end of 35th sessions of EECP treat-
ment, respectively. After 17th session of EECP treatment, both left
CAVI(CAVI-L) and right CAVI(CAVI-R) were lower than those at
baseline, respectively(CAVI-L : 8.090.93 vs 8.670.96; CAVI-R:
8.171.16 vs 8.981.23; all P<0.05). After 35th session of EECP
treatment, both CAVI-L and CAVI-R decreased signiﬁcantly
compared to baseline, respectively (CAVI-L : 7.450.87 vs 8.670.96;
CAVI-R: 7.621.26 vs 8.981.23; all P<0.001). There was also sig-
niﬁcantly difference for CAVI values between 17th and 35th ses-
sion of EECP treatment (CAVI-L : 7.450.87 vs 8.090.93; CAVI-R:
7.621.26 vs 8.171.16 ;all P<0.05). Subgroup analysis showed that
old patients with multimorbidity factors4 had a higher value of
CAVI than those with multimorbidity factors3, and the former group
had more signiﬁcant decreases in CAVI values following either 17th
sessions or 35th sessions of EECP therapy when compared to the latter
group, respectively (p < 0.01).
CONCLUSIONS Besides increasing LVEF, as well as lowering serum
levels of NT-proBNP, Hs-CRP, homocysteine, EECP therapy improves
arterial stiffness by reducing the CAVI values in old patients with
ASCVD, especially in those with multimorbidity factors4. Multi-
morbidity factors are signiﬁcantly associated with the degrees of al-
terations in CAVI parameter derived from EECP treatment. The study
implies EECP treatment is beneﬁcial for artery stiffness in old patients
with ASCVD. The improvement of arteriosclerosis is coincident with
cardiac function changes and inﬂammatory reactions control,
providing further insight into the potential mechanisms of EECP-
mediated amelioration in atherosclerosis.
